Sophiris Bio Inc (SPHS) 0.44 $SPHS
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
Sophiris Bio to Present at the Leerink Global Healthcare Conference
Business Wire - Thu Jan 29, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Leerink Global Healthcare Conference. The presentation is scheduled for Wednesday, February 11, 2015 at 11:05 a.m. EST in New York City.
SPHS: 0.44 (-0.01)
Benign Prostatic Hyperplasia - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/nqt9vr/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AEterna Zentaris - Addex Therapeutics - AmVac - Aphios Corporation - Astellas Pharma Inc. - Ausio Pharmaceuticals - Biolab Sanus Farmaceutica - Chong Kun Dang Pharmaceutical - Chugai Pharmaceutical - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals - IntelGenx - KAEL-GemVax - Kaken Pharmaceutical - Mezzion Pharma - Nymox Pharmaceutical - Ono Pharmaceutical - Quest PharmaTech - SK Chemicals - SOM Biotech - Sophiris Bio - Yungjin Pharm For more information visit http://www.researchandmarkets.com/research/nq..._prostatic
SPHS: 0.44 (-0.01), AEZS: 0.53 (unch), NYMX: 0.36 (-0.02)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.44 (-0.01), ASPX: 65.76 (+2.76), MDVN: 104.71 (+0.67), CYCC: 0.62 (-0.01), OPK: 13.80 (-0.28), NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), REGN: 402.40 (+0.66), MYGN: 34.03 (+0.40), PFE: 34.64 (-0.23), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), BLRX: 1.87 (-0.02), OREX: 5.55 (+0.10), DVA: 73.10 (-3.29), BLCM: 20.00 (-0.81), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), GERN: 3.03 (unch), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.62 (-0.01), CBST: 101.94 (+0.14), SPHS: 0.44 (-0.01), CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02), EXEL: 2.48 (+0.20)
Sophiris's PRX302 Misses Efficacy Threshold In Interim Readout
Daniel Ward - Seeking Alpha - Wed Dec 17, 8:21AM CST
Sophiris (NASDAQ: SPHS ) announced on the morning of December 15th that the company's treatment for benign prostate hyperplasia (BPH) called PRX-302 did not meet the predefined efficacy threshold at the three-month interim analysis. The predefined...
SPHS: 0.44 (-0.01)
Sophiris Plunges on Disappointing Data on its BPH Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:30PM CST
Sophiris Bio Inc.'s (SPHS) shares plummeted 81.5% after the company announced disappointing data from an interim efficacy analysis of its ongoing phase III study on PRX302.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), SPHS: 0.44 (-0.01), SCMP: 15.32 (+0.04)
Investors punish Sophiris
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 12:59PM CST
SPHS: 0.44 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:52AM CST
FRO: 2.96 (+0.07), JRJC: 5.46 (+0.16), TLM: 7.63 (-0.03), SPHS: 0.44 (-0.01), DAKP: 1.91 (+0.07), PHMD: 1.68 (+0.04), HGSH: 3.05 (-0.13), ARDX: 17.14 (+0.71), SRNE: 11.41 (+0.56), NYNY: 6.33 (+0.06), MFI: 10.43 (+0.23), ANFI: 8.84 (-0.42), LNCO: 12.30 (+0.28), QTWW: 2.96 (-0.04), IKGH: 1.13 (+0.01), CRUS: 29.36 (+0.01), MPO: 1.00 (-0.02), LINE: 12.94 (+0.40), CGG: 6.86 (+0.06), UPIP: 0.78 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), SPHS: 0.44 (-0.01), HGSH: 3.05 (-0.13), SN: 15.21 (-0.12), NBG: 1.61 (+0.18), AXAS: 3.46 (+0.04), RVBD: 20.85 (-0.03), OPK: 13.80 (-0.28), ANTH: 3.84 (+0.06), ONVO: 6.34 (+0.07), KEG: 2.14 (+0.08), CALA: 16.11 (+0.62), XCO: 2.52 (+0.20), CRUS: 29.36 (+0.01), ARCP: 9.40 (+0.06)
Sophiris Bio's topsalysin fails to demonstrate efficacy for BPH-associated urinary tract symptoms
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:33AM CST
SPHS: 0.44 (-0.01)
Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Business Wire - Mon Dec 15, 7:00AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and the treatment of localized prostate cancer, today announced findings from an administrative interim analysis of efficacy in its ongoing Phase 3 "PLUS-1" trial of PRX302 as a treatment for lower urinary tract symptoms of BPH. The Independent Data Monitoring Committee (IDMC) reported that a predefined efficacy threshold following treatment was not achieved. This administrative interim analysis was conducted specifically for planning subsequent clinical trials. The ongoing "PLUS-1" study is unaffected by this recommendation, and all patients in the study will continue to be followed to enable the evaluation of the primary efficacy endpoint at 52 weeks.
SPHS: 0.44 (-0.01)
Sophiris Bio to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 7:00AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference. The presentation is scheduled for Tuesday, December 2, 2014 at 12:50 p.m. EST in New York City.
SPHS: 0.44 (-0.01)
Sophiris Bio - Upcoming Catalysts Present Very Attractive Upside
Daniel Ward - at Seeking Alpha - Mon Nov 24, 8:30AM CST
SPHS: 0.44 (-0.01)
Sophiris Bio beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:55PM CST
SPHS: 0.44 (-0.01)
Sophiris Bio Reports Third Quarter Financial Results
Business Wire - Wed Nov 12, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced financial results for the three and nine months ended September 30, 2014.
SPHS: 0.44 (-0.01)
Sophiris Bio to Present at the Stifel 2014 Healthcare Conference
Business Wire - Fri Nov 07, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Stifel 2014 Healthcare Conference. The presentation is scheduled for Tuesday, November 18, 2014 at 3:35 pm EST in New York City.
SPHS: 0.44 (-0.01)
Strength Seen in Sophiris Bio (SPHS): Stock Soars 25% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:46AM CST
Sophiris Bio (SPHS) was a big mover last session, as the company saw its shares surge 25% on the day.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), GWPH: 78.09 (+1.70), SPHS: 0.44 (-0.01)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
Sophiris Bio to Present at the Leerink Global Healthcare Conference
Business Wire - Thu Jan 29, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Leerink Global Healthcare Conference. The presentation is scheduled for Wednesday, February 11, 2015 at 11:05 a.m. EST in New York City. SPHS: 0.44 (-0.01)
Benign Prostatic Hyperplasia - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/nqt9vr/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AEterna Zentaris - Addex Therapeutics - AmVac - Aphios Corporation - Astellas Pharma Inc. - Ausio Pharmaceuticals - Biolab Sanus Farmaceutica - Chong Kun Dang Pharmaceutical - Chugai Pharmaceutical - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals - IntelGenx - KAEL-GemVax - Kaken Pharmaceutical - Mezzion Pharma - Nymox Pharmaceutical - Ono Pharmaceutical - Quest PharmaTech - SK Chemicals - SOM Biotech - Sophiris Bio - Yungjin Pharm For more information visit http://www.researchandmarkets.com/research/nq..._prostatic
SPHS: 0.44 (-0.01), AEZS: 0.53 (unch), NYMX: 0.36 (-0.02)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.44 (-0.01), ASPX: 65.76 (+2.76), MDVN: 104.71 (+0.67), CYCC: 0.62 (-0.01), OPK: 13.80 (-0.28), NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), REGN: 402.40 (+0.66), MYGN: 34.03 (+0.40), PFE: 34.64 (-0.23), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), BLRX: 1.87 (-0.02), OREX: 5.55 (+0.10), DVA: 73.10 (-3.29), BLCM: 20.00 (-0.81), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), GERN: 3.03 (unch), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.62 (-0.01), CBST: 101.94 (+0.14), SPHS: 0.44 (-0.01), CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02), EXEL: 2.48 (+0.20)
Sophiris's PRX302 Misses Efficacy Threshold In Interim Readout
Daniel Ward - Seeking Alpha - Wed Dec 17, 8:21AM CST
Sophiris (NASDAQ: SPHS ) announced on the morning of December 15th that the company's treatment for benign prostate hyperplasia (BPH) called PRX-302 did not meet the predefined efficacy threshold at the three-month interim analysis. The predefined...
SPHS: 0.44 (-0.01)
Sophiris Plunges on Disappointing Data on its BPH Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:30PM CST
Sophiris Bio Inc.'s (SPHS) shares plummeted 81.5% after the company announced disappointing data from an interim efficacy analysis of its ongoing phase III study on PRX302.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), SPHS: 0.44 (-0.01), SCMP: 15.32 (+0.04)
Investors punish Sophiris
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 12:59PM CST
SPHS: 0.44 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:52AM CST
FRO: 2.96 (+0.07), JRJC: 5.46 (+0.16), TLM: 7.63 (-0.03), SPHS: 0.44 (-0.01), DAKP: 1.91 (+0.07), PHMD: 1.68 (+0.04), HGSH: 3.05 (-0.13), ARDX: 17.14 (+0.71), SRNE: 11.41 (+0.56), NYNY: 6.33 (+0.06), MFI: 10.43 (+0.23), ANFI: 8.84 (-0.42), LNCO: 12.30 (+0.28), QTWW: 2.96 (-0.04), IKGH: 1.13 (+0.01), CRUS: 29.36 (+0.01), MPO: 1.00 (-0.02), LINE: 12.94 (+0.40), CGG: 6.86 (+0.06), UPIP: 0.78 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), SPHS: 0.44 (-0.01), HGSH: 3.05 (-0.13), SN: 15.21 (-0.12), NBG: 1.61 (+0.18), AXAS: 3.46 (+0.04), RVBD: 20.85 (-0.03), OPK: 13.80 (-0.28), ANTH: 3.84 (+0.06), ONVO: 6.34 (+0.07), KEG: 2.14 (+0.08), CALA: 16.11 (+0.62), XCO: 2.52 (+0.20), CRUS: 29.36 (+0.01), ARCP: 9.40 (+0.06)
Sophiris Bio's topsalysin fails to demonstrate efficacy for BPH-associated urinary tract symptoms
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:33AM CST
SPHS: 0.44 (-0.01)
Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Business Wire - Mon Dec 15, 7:00AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and the treatment of localized prostate cancer, today announced findings from an administrative interim analysis of efficacy in its ongoing Phase 3 "PLUS-1" trial of PRX302 as a treatment for lower urinary tract symptoms of BPH. The Independent Data Monitoring Committee (IDMC) reported that a predefined efficacy threshold following treatment was not achieved. This administrative interim analysis was conducted specifically for planning subsequent clinical trials. The ongoing "PLUS-1" study is unaffected by this recommendation, and all patients in the study will continue to be followed to enable the evaluation of the primary efficacy endpoint at 52 weeks. SPHS: 0.44 (-0.01)
Sophiris Bio to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 7:00AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference. The presentation is scheduled for Tuesday, December 2, 2014 at 12:50 p.m. EST in New York City. SPHS: 0.44 (-0.01)
Sophiris Bio - Upcoming Catalysts Present Very Attractive Upside
Daniel Ward - at Seeking Alpha - Mon Nov 24, 8:30AM CST
SPHS: 0.44 (-0.01)
Sophiris Bio beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:55PM CST
SPHS: 0.44 (-0.01)
Sophiris Bio Reports Third Quarter Financial Results
Business Wire - Wed Nov 12, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced financial results for the three and nine months ended September 30, 2014. SPHS: 0.44 (-0.01)
Sophiris Bio to Present at the Stifel 2014 Healthcare Conference
Business Wire - Fri Nov 07, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Stifel 2014 Healthcare Conference. The presentation is scheduled for Tuesday, November 18, 2014 at 3:35 pm EST in New York City. SPHS: 0.44 (-0.01)
Strength Seen in Sophiris Bio (SPHS): Stock Soars 25% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:46AM CST
Sophiris Bio (SPHS) was a big mover last session, as the company saw its shares surge 25% on the day.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), GWPH: 78.09 (+1.70), SPHS: 0.44 (-0.01)
